Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Bachner

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Current Opinion in Urology|June 25, 2009
Second-line therapy in bladder cancerMark Bachner, Maria De Santis
Therapeutics and Clinical Risk Management|April 2, 2009
Vinflunine in the treatment of bladder cancerMark Bachner, Maria De Santis
Current Opinion in Urology|September 1, 2007
New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladderMaria De Santis, Mark Bachner
Onkologie|June 14, 2008
[Organization, administration, and performance of clinical studies]Mark Bachner, Tanja Steininger, Margit Gneist
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Current Opinion in Urology|June 25, 2009
Second-line therapy in bladder cancerMark Bachner, Maria De Santis
Therapeutics and Clinical Risk Management|April 2, 2009
Vinflunine in the treatment of bladder cancerMark Bachner, Maria De Santis
Current Opinion in Urology|September 1, 2007
New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladderMaria De Santis, Mark Bachner
Onkologie|June 14, 2008
[Organization, administration, and performance of clinical studies]Mark Bachner, Tanja Steininger, Margit Gneist
Pageof 1